Status:
UNKNOWN
Protective Effect of Aspirin on COVID-19 Patients
Lead Sponsor:
Xijing Hospital
Conditions:
Novel Coronavirus Pneumonia
Aspirin
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
COVID-19 has a high infection rate and mortality, and serious complications such as heart injury cannot be ignored. Cardiac dysfunction occurred in COVID-19 patients, but the law and mechanism of card...
Detailed Description
1. COVID-19 has a high infection rate and mortality, and serious complications such as heart injury cannot be ignored. At present, the scale and harm of COVID 19 (Novel coronavirus pneumonia (NCP)...
Eligibility Criteria
Inclusion
- The patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent,
- Subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.The detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by Real-time -PCR, 2. Virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus,
- Chest image confirmed pulmonary involvement;
- fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough;
- Onset time ≤14 days;
- Agree not to participate in another study until completion of the 14-day study; If you need to withdraw from this study;
- The subjects had not taken aspirin for nearly one month prior to the screening period.
- Can follow the study or follow up procedure. -
Exclusion
- Women who have recently been pregnant or breast-feeding.
- Having a history of active gastrointestinal bleeding in the past 3 months.
- Blood routine examination showed that the platelet count was \< 30×109/L.
- Patients with coagulation disorders.
- Unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required.
- Having no capacity for civil conduct.
- A history of drug or alcohol abuse.
- Allergic to aspirin.
- Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc.
- Patients with cardiac stent placement (\< 1 year).
- Any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, AIDS, viral hepatitis, etc.
Key Trial Info
Start Date :
February 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04365309
Start Date
February 10 2020
End Date
June 1 2020
Last Update
April 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cai Yue
Xi'an, Shaanxi, China, 710032